Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma
Clinical trial NCT02507583 · COMPLETED
Trial details
- NCT number
- NCT02507583
- Sponsor
- david andrews
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-01
- Primary completion
- 2018-03-06
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.